Warren Li, PhD
Dr. Weimin (Warren) Li serves as VP, Translational Medicine at Overland Pharmaceuticals.
Prior to Overland, Dr. Li was Translational Development Head, Cell Therapies at Takeda Pharmaceuticals leading translational and precision medicine strategies for Takeda’s cell therapy portfolio. Before Takeda, Dr. Li was a Director of Translational Medicine/Precision Medicine at AstraZeneca, where he led translational medicine, clinical biomarkers and diagnostics development for AZ’s immuno-oncology programs in gastrointestinal, genitourinary, and head & neck cancers. Prior to joining AstraZeneca, Weimin spent 10 years within the Oncology Translational Research group at Janssen Pharmaceuticals, where he led the transition from preclinical development to FIH of several IO assets. Weimin also led clinical biomarkers strategies for several full development programs, including abiraterone (anti-androgen), niraparib (PARPi) and trabectedin. Overall, Dr. Li brings over 18 years of experience in oncology drug development with a focus on translational medicine.
Dr. Li received his PhD from the University of Illinois at Urbana-Champaign and completed his postdoc training at the University of Chicago. He received his MS from Chinese Academy of Sciences and BS from Fudan University.